As a result of this change, IGC Pharma will file a transition report on Form 10-K with the U.S. Securities and Exchange Commission (the "SEC") covering the nine-month period from April 1, 2025, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback